69 results about "Lymphopoiesis" patented technology

The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of B lymphocytes and (2) anti-4-1BB (anti-CD137) antibody for inhibiting proliferation and activation and inducing death of B lymphocytes.

The invention provides ganoderma lucidum polysaccharide and a preparation method thereof. The ganoderma lucidum polysaccharide is obtained through carrying out water extraction and ultrafiltration on a ganoderma lucidum fruiting body, decoloring and then freeze drying. The decolored ganoderma lucidum polysaccharide has remarkably improved immunocompetence and can stimulate macrophage to generate nitric oxide and stimulate lymphopoiesis.

The recombinant staphylococcus aureus enterotoxin M as one kind of superantigen with the amino acid sequence as shown in SEQ ID No. 1 is obtained through recombining gene originated from staphylococcus aureus and coding SEM with one kind of plasmid vector, transforming to proper host for expressing, and affiliation purifying. It is proved through extracorporeal mouse spleen lymphopoiesis experiment and tumor cell inhibiting experiment that the recombinant protein has typical superantigen activity stronger than that of SEC and may be applied in preparing medicine for stimulating lymphopoiesis and inhibiting tumor cell growth. The present invention is suitable for preparing high purity enterotoxin with superantigen activity and developing superantigen preparation. The present invention has reasonable design, efficient expression on recombinant SEM in the expression strength of about 15-25 % of staphylococcus aureus protein, and other advantages.

The present invention provides a kind of recombinant staphylococcus aureus enterotoxin I prepared through genetic engineering process, and the protein is one kind of super antigen with the amino acid sequence of SEQ ID No. 1. The recombinant plasmid is reconstructed with pGEX-4T-1 and the nucleotide sequence of SEQ ID No. 2. Extracorporeal experiment shows that the prepared high purity recombinant SEI protein can excite the splenic lymphopoiesis of mouse effectively in dosage depending relationship and the excited splenic lymphocyte of the mouse has obvious tumor cell killing effect. Compared with available staphylococcus aureus enterotoxin C as the main effective component in the staphylococcus aureus filtrate preparation, the recombinant SEI protein has even high super antigen activity and may be prepared into super antigen preparation for inhibiting tumor growth effectively.

The present invention relates to novel semi-synthetic macrolides with anti-inflammatory activity. More specifically, the present invention relates to 14- and 15-membered macrolides substituted at the 4" position, their pharmaceutically acceptable derivatives, their preparation methods and intermediates, pharmaceutical compositions containing them and Their activity and use in the treatment of human and animal inflammatory diseases and disorders, particularly diseases associated with excessive secretion of TNF-alpha, IL-1, IL-8, IL-2 or IL-5; and/or as Activity and use of inhibitors of lymphocyte hyperproliferation and/or granulocyte hyperdegranulation.

Uses for WSX ligands in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for stimulating hematopoiesis (e.g., myelopoiesis, erythropoiesis and especially, lymphopoiesis) using a WSX ligand (e.g., anti-WSX receptor agonist antibodies or OB protein), and optionally another cytokine, are described.

The invention discloses a screening method of immunologic function evaluation indexes of an anthropopathic nose-only rat. The screening method comprises the following steps: taking serum, splenic lymphocyte, splenic lymphocyte culture supernate, peritoneal macrophage and blood of an air breathing rat as a normal contrast group, and taking serum, splenic lymphocyte, splenic lymphocyte culture supernate, peritoneal macrophage and blood of a rat continuously smoking cigarettes through the nose as a smoking group; detecting the multiplication capacities of the lymphocyte, the swallowing conditions of the peritoneal macrophage, the contents of IL-6, TNF-alpha, Ig, IgG and IgE and the differential counting of leukocyte of each group; and finally, screening out five indexes of lymphopoiesis stimulation indexes, the contents of the IL-6, the IgG and the IgE and the differential counting of leukocyte as sensitive and stable evaluation indexes for reflecting the changes of the immunologic functions of the smoking rat. The method is scientific and comprehensive, and the screened evaluation indexes have good sensitive stability.

The invention provides a detection method of immune functions of mesenchymal stem cells. The detection method of the immune functions of the mesenchymal stem cells comprises the following steps: (1) co-culturing umbilical cord mesenchymal stem cells and peripheral blood mononuclear cells so as to obtain a sample to be tested; and (2) detecting proliferative activity of lymphocytes and proportion of lymphocyte subsets in the sample to be tested. The detection method of the immune functions of the mesenchymal stem cells is suitable for non-diagnostic purposes. According to the detection method of the immune functions of the mesenchymal stem cells provided by the embodiment of the invention, the mesenchyma stem cells and the human peripheral blood mononuclear cells are co-cultured so as to obtain the sample to be tested; and then, the proportion of the lymphocyte subsets and the proliferative activity of the lymphocytes in the sample to be tested are detected so as to evaluate the immunoregulatory capacity of the mesenchymal stem cells. The greater the changes of the proportion of the lymphocyte subsets and the proliferative activity of the lymphocytes are, the stronger the immune functions and the better the quality of the mesenchymal stem cells are.

The invention discloses two CD8+T cell dominant epitopes of VPNSSLVEN and SQFLSLSLL based on toxoplasmagondii bradyzoite specific surface antigens, wherein six CD8+T cell epitopes with H-2 restriction and high affinity are screened according to the protein sequences of the bradyzoite specific surface antigens of SAG2C, -2C and -2X; BALB/c mice are actively immunized by the screened epitope polypeptides; determinations for a lymphopoiesis level and a cell factor content, and an immune protection evaluation for epitope vaccines are performed after the immunization. The result indicates that powerful cell immunization can be generated by inducing the mice via the epitope vaccinesm, wherein the two antigen peptides of VPNSSLVEN and SQFLSLSLL are provided to be great in the capacity of stimulating T cell proliferation, as well as capable of inducing the mice to secrete protective cell factors and immune protection, being used as the epitope vaccines effectively resisting toxoplasmagondii infection, and reducing an encystations rate in the brain tissue of a host.

The invention relates to preparation and application of an infectious bursal disease (IBD) protein engineering vaccine. The preparation method comprises the following steps: connecting B cell neutralizing epitope and T cell immunizing epitope of IBDV (infectious bursal disease virus) primary structure proteins VP2 and VP3 as a vaccine frame structure through a flexible linker, connecting with cell factor poultry interleukin 15(chIL-15) in series, cloning into a pRSETB vector, transforming Escherichia coli, fermenting, purifying, emulsifying and the like to obtain the IBD protein engineering vaccine with ideal immunogenicity. The invention also relates to an application method of the vaccine. The animal experiment indicates that the IBD protein engineering vaccine has equivalent effects to the live virus vaccine on the humoral immunity and cellular immunity level, and can stimulate the generation of T lymphopoiesis immunoreaction on the cellular level and the generation of antibody immunoreaction with virus neutralizing activity on the humoral level. The attacking protection test indicates that the IBD protein engineering vaccine group has obviously better effects than the live vaccine group.

The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and / or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111).The antibodies of the invention are suitable for use inorder to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Val-Sta-Leu- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Pro-Pro-Tyr-Val-Sta-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of a peptide chain, 4) cyclization of the peptide chain. The cyclic peptide compounds which are provided with the residue fragment of Val-Sta-Leu- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A3HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A3HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

The invention discloses a preparation of gene immunization treating tumor used for veins, which is composed of replication deficient adenovirus loading human telomerase reverse transcriptase C-terminal polypeptide hTERTC27 and an acceptable pharmaceutic adjuvant. The anti-tumor gene preparation rAdv-hTERTC27 of the invention has high transfection efficiency, and is more effective on the increment and the apoptosis regulation of the tumor cell. The anti-tumor gene preparation of the invention can effectively lead the peptides transfection to enter into the dendritic cell DCs, so as to activate the DCs, secrete IFN-gamma, IL-2, increase and further stimulate T lymphopoiesis, promote the T lymphocyte to generate the special killing effect CTL corresponding to the tumor cell, and immunoregulation is carried out on the tumor.

The present invention relates to one kind of staphylococcus aureus DNA vaccine pcDNA3.1(+)-Minigene and its preparation process. Immunological mouse test shows that the staphylococcus aureus DNA vaccine pcDNA3.1(+)-Minigene of the present invention can stimulate mouse body to generate obvious and lasting specific lymphopoiesis reaction and humoral immunity in certain level and in obvious difference (P<0.05) to that of pcDNA3.1 inoculating negative control group. In addition, the toxicity antagonizing test shows that pcDNA3.1(+)-Minigene plasmid can induce mouse to generate staphylococcus aureus resisting antibody to protect the immunized mouse.

The invention relates to cyclic peptide used as immunosuppressant and carried with -Pro-Sta-Tyr- residue fragment as well as ring (Ile-Ile-Pro-Sta-Tyr-Val-Pro-Leu). The synthesis process of the invention is as follows: (1) amino protecting group is removed; (2) synthesized peptide is completed; (3) peptide chain cutting is carried out; (4) peptide chain cyclization is completed. Therefore, a cyclic peptide compound, which has high yield, high purity and -Pro-Sta-Tyr- residue fragment and can be used as immunosuppressant, can be obtained; moreover, the compound has higher immunosuppression activity. The experiments on the inhibition of A2HS1 on mouse delayed hypersensitivity, the influence on the phagocytic capability of macrophage and the inhibition on lymphopoiesis show that the A2HS1 represents stronger natural immunosuppression than HS-1 and reaches or exceeds positive contrast (cyclosporin) immunosuppression.

The invention belongs to the fields of medicine and bioengineering, and discloses an immunoregulation peptide, and a preparation method and application thereof. The amino acid sequence of the immunoregulation is disclosed as SEQ ID NO:1. The immunoregulation peptide has high T lymphopoiesis promoting function, and can be used for preparing T lymphopoiesis promoting drugs.

The invention discloses a compound Chinese traditional medicine preparation for inducing immune tolerance and preparing method and application thereof. The compound Chinese traditional medicine preparation comprises 2-30 parts of roots of Chinese thorowax, 3-31 parts of moutan bark, 4-32 parts of radix paeoniae alba, 5-33 parts of radix curcumae and 6-35 parts of liquorice. The above components are prepared according to the proportion, to be smashed, soaked with water, decocted, filtered, centrifuged and dried to be made into capsules, oral liquid, tablets and the like. The compound Chinese traditional medicine preparation can induce generation of DC regs of high-expression CD11b and low-expression HLA-DR/CD86/CD80, the DCregs generated through inducing can effectively inhibit DC-mediated lymphopoiesis and promote secretion of cytokines IL-10; a receptor mice is induced to tolerate the iso-allotransplantation skin; no influence on the motility rate of DC cells and the hepatorenal function of the receptor mice is generated, and the compound Chinese traditional medicine preparation is effective and low-toxic and induces immune tolerance.